- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05651672
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
December 7, 2022 updated by: Tianjin Medical University Cancer Institute and Hospital
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations That Failed Standard Therapy
This study is a prospective single-arm phase II study to evaluate the efficacy and safety of Pemigatinib in the advanced gastrointestinal cancer with FGFR 1-3 alterations and failed standard therapy.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wei Lu
- Phone Number: 3091 +86-22-23340123
- Email: mail4luwei@163.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Recruiting
- Tianjin Medical University Cancer Institute & Hospital
-
Contact:
- Wei Lu
- Phone Number: 3089 +86-22-23340123
- Email: mail4luwei@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 18 or older
- Histologically or cytologically confirmed unresectable advanced, recurrent or metastatic gastrointestinal cancer
- Have at least one measurable lesion according to RECIST v1.1
- With histologically confirmed FGFR1-3 alterations, including but not limited to amplification, mutation, fusion/rearrangement
- Disease progression after prior standard therapy
- No previous use of small molecule multi-target inhibitors targeting the FGFR pathway (including but not limited to anlotinib, lenvatinib, sorafenib, apatinib)
- ECOG performance status of 0~1
- Expected survival time > 3 months
- Sufficient organ functions
- Negative pregnancy test results of childbearing age women
- Patients at risk of conception (including their partners) need to use contraception
Exclusion Criteria:
- Diagnosed with malignant tumors other than gastrointestinal cancer within 5 years before the first dose, excluding radically cured cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and/or radically resected carcinoma in situ
- Prior receipt of selective FGFR inhibitors
- Have received any other investigational drug or participated in another interventional clinical trial within 28 days before the first dose, or have received anti-tumor drug treatment within 28 days before the first dose (including Chinese herbal medicine with anti-tumor indications)
- Have not recovered ( ≤ grade 1 or reaching the baseline, excluding asthenia and alopecia) from toxicity and/or complications caused by any intervention before the start of treatment
- Known symptomatic central nervous system metastasis and/or carcinomatous meningitis.
- Known history of allotransplantation or allogeneic hematopoietic stem cell transplantation
Abnormal laboratory parameters listed below:
- Serum phosphate > upper limit of normal (ULN)
- Serum calcium exceeds the normal range, or the calcium concentration corrected for serum albumin exceeds the normal range when serum albumin exceeds the normal range
- Potassium level < lower limit of normal (LLN)#potassium levels can be corrected by supplements at screening
- Known history of human immunodeficiency virus (HIV) infection or confirmed with positive immune test results
- Presence of severe infection in the active phase or with poor clinical control
- Pleural effusion, ascites, or pericardial effusion with obvious clinical symptoms that require drainage
- Acute or chronic active hepatitis B or C infection
- Clinically significant or uncontrolled heart diseases, including unstable angina, acute myocardial infarction within 6 months before the first dose, grade III/IV congestive heart failure (New York Heart Association), and uncontrolled arrhythmia (patients with pacemakers or with atrial fibrillation but well controlled heart rate are allowed)
- ECG changes or medical history considered clinically significant by the investigator, QTcF interval > 480 ms at screening, JTc interval can be used instead of QTc interval (in such cases, JTc must be ≤ 340 ms) for patients with intraventricular conduction block (QRS interval > 120 ms)
- Uncontrolled hypertension (systolic pressure > 160 mmHg or diastolic pressure > 100 mmHg) after the optimal medical treatment, or a history of hypertensive crisis or hypertensive encephalopathy
- Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis with Child-Pugh grade B or C
- Have received a major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose, or will receive a major surgery during the study treatment period
- Not fully recovered from toxicity and/or complications of a major surgery before the study treatment
- Pregnant or lactating women, or patients expected to conceive or give birth during the study period from the screening to the completion of the safety follow-up visit (90 days after the last dose for male subjects)
- Have received radiotherapy within 4 weeks before the first dose.
- History of disorders of calcium and phosphorus metabolism or systemic electrolyte metabolism imbalance with ectopic calcification of soft tissues (excluding calcification of soft tissues such as skin, kidneys, tendon, or blood vessels without systemic electrolyte metabolism imbalance caused by injury, disease, and old age)
- Clinically significant corneal or retinal diseases confirmed by ophthalmological examination
- Prior receipt of any potent CYP3A4 inhibitor or inducer within 14 days or 5 half lives (whichever is shorter) before the first dose. Ketoconazole is allowed for external use
- Known allergic reactions to pemigatinib or excipients of pemigatinib
- Unable or unwilling to swallow pemigatinib or are suffering from significant digestive system diseases that may interfere with absorption, metabolism, or excretion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: experimental group
Pemigatinib
|
13.5mg, po, 2 weeks on/1 week off, Q3W
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR)
Time Frame: up to 2 years
|
Defined as proportion of patients who have a best response of complete response (CR) + partial response (PR) according to the RECIST 1.1 criteria
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progress Free Survival (PFS)
Time Frame: Up to 4 years
|
Defined as the time from enrollment to disease progression or death (whichever occurs first)
|
Up to 4 years
|
Overall Survival (OS)
Time Frame: Up to 4 years
|
Defined as the time from enrollment to the death
|
Up to 4 years
|
Duration of Response (DOR)
Time Frame: up to 4 years
|
Defined as the time from the date of CR or PR to PD
|
up to 4 years
|
Disease Control Rate (DCR)
Time Frame: Up to 2 years
|
Defined as proportion of patients who have a best response of complete response (CR) + partial response (PR) + stable disease (SD) according to the RECIST1.1 criteria
|
Up to 2 years
|
Adverse Events (AEs)
Time Frame: Up to 2 years
|
Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 2, 2022
Primary Completion (Anticipated)
December 1, 2024
Study Completion (Anticipated)
December 1, 2026
Study Registration Dates
First Submitted
December 7, 2022
First Submitted That Met QC Criteria
December 7, 2022
First Posted (Estimate)
December 15, 2022
Study Record Updates
Last Update Posted (Estimate)
December 15, 2022
Last Update Submitted That Met QC Criteria
December 7, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TJ-0046
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Cancer
-
Five Prime Therapeutics, Inc.CompletedGastric Cancer | Gastrointestinal Cancer | Gastrointestinal Cancer MetastaticUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); Dartmouth-Hitchcock Medical Center; West Virginia... and other collaboratorsActive, not recruitingGynecologic Cancer | Thoracic Cancer | Gastrointestinal Cancer | Other CancerUnited States
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, Germany; 4SC AGUnknownCancer | GI CancerUnited Kingdom
-
Boehringer IngelheimCompletedGastrointestinal Cancer, MetastaticBelgium, United States, France, Japan, China
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Apceth GmbH & Co. KGTerminatedAdvanced Gastrointestinal CancerGermany
-
Fudan UniversityNot yet recruitingOligometastatic Gastrointestinal CancerChina
-
Bristol-Myers SquibbCompletedUpper Gastrointestinal CancerCanada
-
Intima Bioscience, Inc.Masonic Cancer Center, University of MinnesotaRecruitingGastrointestinal Neoplasms | Stomach Cancer | Pancreatic Cancer | Esophageal Cancer | Colon Cancer | Gastrointestinal Cancer | Colo-rectal Cancer | Gall Bladder Cancer | Cancer of Gastrointestinal Tract | Gastrointestinal Epithelial Cancer | Cancer, GastrointestinalUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC Utrecht; University of Cambridge; IRCCS Fondazione Stella MarisRecruitingGastrointestinal Cancer MetastaticNetherlands, United Kingdom, Italy
Clinical Trials on Pemigatinib
-
The First Affiliated Hospital of Soochow UniversityRecruitingNon-Small Cell Lung CancerChina
-
Sun Yat-sen UniversityNot yet recruitingLocally Advanced Unresectable Gastric CancerChina
-
Wuhan Union Hospital, ChinaRecruiting
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Institut für Klinische Krebsforschung IKF GmbH...Incyte Biosciences International SàrlRecruitingIntrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Gene Translocation | FGFR2 Gene RearrangementGermany
-
The Fourth Affiliated Hospital of Zhejiang University...Second Affiliated Hospital, School of Medicine, Zhejiang UniversityRecruitingAdvanced Non Small Cell Lung CancerChina
-
Incyte CorporationTerminatedAdvanced or Metastatic Solid Tumors | FGFR Mutations | FGFR TranslocationsUnited States
-
Incyte CorporationH. Lee Moffitt Cancer Center and Research InstituteNo longer available
-
The First Affiliated Hospital of Xiamen UniversityRecruiting